Drug Profile
Research programme: antibody therapeutics - Genmab
Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Genmab
- Class Antibodies; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
- No development reported Infections
Most Recent Events
- 28 Mar 2023 Preclinical development for Cancer is ongoing in Denmark (Genmab pipeline, March 2023)
- 02 Nov 2016 Preclinical trials in Cancer in Denmark (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Denmark (Parenteral)